ZyCoV-D
ZyCoV-D
ZyCoV-D (pronounced: /zaɪ.kɒv di:/) is a vaccine developed for the prevention of COVID-19, a disease caused by the SARS-CoV-2 virus.
Etymology
The name "ZyCoV-D" is derived from the name of the company that developed it, Zydus Cadila, and the disease it is designed to prevent, COVID-19. The "D" in the name stands for DNA, as it is a DNA-based vaccine.
Description
ZyCoV-D is a plasmid DNA vaccine. It uses a small, circular piece of DNA called a plasmid that has been engineered to carry the gene for a part of the SARS-CoV-2 virus known as the spike protein. When the vaccine is injected, the body's cells read the DNA sequence and produce the spike protein, which the immune system recognizes as foreign and mounts an immune response against.
Administration
ZyCoV-D is administered in three doses, with each dose given at an interval of 28 days. It is the world's first DNA-based vaccine for COVID-19 to be administered in humans and the first to be administered using a needle-free system.
Efficacy
Clinical trials have shown that ZyCoV-D is effective at preventing COVID-19. The vaccine has been found to be safe and well-tolerated in all age groups.
Related Terms
External links
- Medical encyclopedia article on ZyCoV-D
- Wikipedia's article - ZyCoV-D
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski